Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer

被引：0
作者：
Wen Ouyang
Jing Yu
Yan Zhou
Jing Hu
Zhao huang
Junhong Zhang
Conghua Xie
机构：
[1] Zhongnan Hospital of Wuhan University,Department of Radiation and Medical Oncology
[2] Zhongnan Hospital of Wuhan University,Hubei Key Laboratory of Tumor Biological Behaviors
[3] Zhongnan Hospital of Wuhan University,Hubei Clinical Cancer Study Center
来源：
BMC Cancer | / 20卷
关键词：
Non-small cell lung cancer; Epidermal growth factor receptor; Brain metastases; Risk factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
[21]   Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study [J].
Wang, Xia ;
Cai, Jing ;
Zeng, Zhimin ;
Liu, Anwen .
BMC CANCER, 2021, 21 (01)
[22]   Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study [J].
Xia Wang ;
Jing Cai ;
Zhimin Zeng ;
Anwen Liu .
BMC Cancer, 21
[23]   Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer [J].
Baik, Christina S. ;
Chamberlain, Marc C. ;
Chow, Laura Q. .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) :1268-1278
[24]   MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer [J].
Yan, D. ;
Huelse, J. ;
Parker, R. ;
Wang, X. ;
Frye, S. ;
Earp, H. S. ;
Deryckere, D. ;
Graham, D. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) :S1147-S1147
[25]   Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib [J].
Kunimasa, Kei ;
Kamada, Risa ;
Oka, Toru ;
Oboshi, Makiko ;
Kimura, Madoka ;
Inoue, Takako ;
Tamiya, Motohiro ;
Nishikawa, Tatsuya ;
Yasui, Taku ;
Shioyama, Wataru ;
Nishino, Kazumi ;
Imamura, Fumio ;
Kumagai, Toru ;
Fujita, Masashi .
JACC: CARDIOONCOLOGY, 2020, 2 (01) :1-10
[26]   EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment [J].
Madeddu, Clelia ;
Donisi, Clelia ;
Liscia, Nicole ;
Lai, Eleonora ;
Scartozzi, Mario ;
Maccio, Antonio .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (12)
[27]   Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer [J].
Di Marino, Pietro ;
Chiapperino, Cosima ;
Primavera, Francesca Chiara ;
Martino, Maria Teresa ;
Brocco, Davide ;
Carella, Consiglia ;
Grassadonia, Antonino ;
Tinari, Nicola ;
De Tursi, Michele .
ONCOTARGETS AND THERAPY, 2022, 15 :407-410
[28]   Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer [J].
Lee, Victor H. F. .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 :4-6
[29]   Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer [J].
Santarpia, Mariacarmela ;
Menis, Jessica ;
Chaib, Imane ;
Cao, Maria Gonzalez ;
Rosell, Rafael .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) :831-840
[30]   Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer [J].
Yamada, Tadaaki ;
Hirai, Soichi ;
Katayama, Yuki ;
Yoshimura, Akihiro ;
Shiotsu, Shinsuke ;
Watanabe, Satoshi ;
Kikuchi, Toshiaki ;
Hirose, Kazuki ;
Kubota, Yutaka ;
Chihara, Yusuke ;
Harada, Taishi ;
Tanimura, Keiko ;
Takeda, Takayuki ;
Tamiya, Nobuyo ;
Kaneko, Yoshiko ;
Uchino, Junji ;
Takayama, Koichi .
CANCER MEDICINE, 2019, 8 (04) :1521-1529
12345